Human umbilical cord blood mononuclear cells transplantation for perinatal brain injury

Xi, Yufeng; Yue, Guang H.; Gao, Siyang; Ju, Rong; Wang, Yujia

doi:10.1186/s13287-022-03153-y

Cited by 21 publications

(5 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cells can modulate the immune response and reduce inflammation, which are important factors in intimal hyperplasia development, 17 and it may promote vascular repair and inhibit the development of intimal hyperplasia. 18 The combination of umbilical cord mesenchymal stem cells and HIF-1α can enhance these angiogenic properties and improve the outcomes of arteriovenous fistula creation. Zhang et al conducted a study that found human umbilical cord mesenchymal stem cells produced exosomes promote angiogenesis through HIF-1α, which is beneficial to fracture healing.…”

Section: Level Of Hif-1αmentioning

confidence: 99%

Umbilical cord mesenchymal stem cell; a potential therapy on reducing intimal hyperplasia in rabbit arteriovenous fistula (AVF) model, analysis the expression of HIF-1a, eNOS, and MMP-2

Habibie,

Emril,

Azharuddin

et al. 2023

F1000Res

View full text Add to dashboard Cite

Introduction: AVF is the best option for hemodialysis access, but its patency rate drops after one year. UC-MSCs were used to reduce inflammation and promote vascular tissue repair in AVF rabbit models. Methods: In this study, 28 male domestic rabbits (Lepus Domestica) were divided into four groups: KN as a negative control, KP as a positive control with placebo therapy, P1 as the treatment group with in situ UC-MSCs, and P2 as the treatment group with intravenous UC-MSCs. The UC-MSCs dose administered was 1,000,000 cells per kilogram of body weight. After 28 days, all groups of rabbit models with AVF were sacrificed. HIF-1α, eNOS, and MMP-2 levels were measured using ELISA Sandwich methods and analyzed using a one-way ANOVA test followed by post hoc Duncan test. Results: The study found significant differences in HIF-1α, eNOS, and MMP-2 levels among the treatment groups. P3 and P4 treatments did not significantly differ in HIF-1α levels, but P3 had a lower average HIF-1α level than P4. The KP group had the highest concentration of eNOS, significantly higher than P1, P2, and KN. ENOs concentration decreased in P1 and P2 and was significantly lower than KP. The level of MMP-2 in AVF rabbits that received intravenous UC-MSCs was significantly higher than that of healthy rabbits (KN), but significantly lower than the AVF rabbit group that received a placebo. The MMP-2 level in AVF rabbits receiving in situ UC-MSCs was significantly lower than in the placebo and intravenous UC-MSC groups. Conclusion. This study suggests that local delivery of in situ UC-MSCs targeting HIF-1α, eNOS, and MMP-2 levels can effectively reduce intimal hyperplasia (IH) in rabbit models of AVF, potentially preventing early AVF failure and serving as a promising therapy to prevent and reduce IH in AVF.

show abstract

Section: Level Of Hif-1αmentioning

confidence: 99%

Umbilical cord mesenchymal stem cell; a potential therapy on reducing intimal hyperplasia in rabbit arteriovenous fistula (AVF) model, analysis the expression of HIF-1a, eNOS, and MMP-2

Habibie,

Emril,

Azharuddin

et al. 2023

F1000Res

View full text Add to dashboard Cite

show abstract

“…UCB refers to blood within the umbilical cord and blood vessels surrounding the fetal component of the placenta. [17] Numerous cell types comprise UCB including HSCs, MSCs, Tregs, monocytes and EPCs. [81] In our review, all four outcomes which demonstrated statistically significant differences between UCB cell types were associated with a favoured modification of treatment effect in MSCs over MNCs.…”

Section: Ucb Cell Typementioning

confidence: 99%

“…[9,[13][14][15] Umbilical cord blood (UCB)-derived cell therapy is one of the most prominent emerging interventions in this area of research and has received a large amount of attention in both preclinical and clinical studies. [16][17][18][19] In part A of this review, we demonstrated UCB-derived cells (UCBCs) were effective in improving both neuropathological and behavioural outcomes in preclinical models. The specific outcomes investigated were apoptosis, astrogliosis, infarct size, microglial activation, oligodendrocyte number, neuroinflammation and motor function.…”

Section: Introductionmentioning

confidence: 99%

Umbilical cord blood-derived cell therapy for perinatal brain injury: A systematic review & meta-analysis of preclinical studies - Part B

Purcell

Nguyen

Smith

et al. 2022

Preprint

View full text Add to dashboard Cite

IntroductionWe previously described preclinical literature, which supports umbilical cord blood-derived cell (UCBC) therapy use for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient populations and intervention characteristics.ObjectivesTo systematically review effects of UCBCs on brain outcomes in animal models of perinatal brain injury across subgroups to better understand contribution of model type (preterm versus term), brain injury type, UCB cell type, route of administration, timing of intervention, cell dosage and number of doses.MethodsA systematic search of MEDLINE and Embase databases was performed to identify studies using UCBC therapy in animal models of perinatal brain injury. Subgroup differences were measured by chi2test where possible.ResultsDifferential benefits of UCBCs were seen in a number of subgroup analyses including intraventricular haemorrhage (IVH) vs. hypoxia ischaemia (HI) model (apoptosis white matter (WM): chi2=4.07; P=0.04, neuroinflammation-TNF-α: chi2=5.99; P=0.01), UCB-derived mesenchymal stromal cells (MSCs) vs. UCB-derived mononuclear cells (MNCs) (oligodendrocyte WM: chi2=5.01; P=0.03, neuroinflammation-TNF-α: chi2=3.93; P=0.05, apoptosis grey matter (GM), astrogliosis WM) and intraventricular/intrathecal vs. systemic routes of administration (microglial activation GM: chi2=7.51; P=0.02, astrogliosis WM: chi2=12.44; P=0.002). We identified a serious risk of bias and overall low certainty of evidence.ConclusionsPreclinical evidence suggests greater efficacy for UCBCs in IVH compared to HI injury model, use of UCB-MSCs compared to UCB-MNCs, and use of local administrative routes compared to systemic routes in animal models of perinatal brain injury. Further research is needed to improve certainty of evidence found and address knowledge gaps.SIGNIFICANCE STATEMENTIn neonatal medicine there is a clear need for the development of new therapies that can provide neuroregenerative benefits for infants with brain injuries. This review offers a unique and comprehensive resource to inform the development of future preclinical and clinical studies. In part A of this review, we systematically reviewed the preclinical literature surrounding UCBCs as a therapy for perinatal brain injury. In part B of this review, we investigated the effect variables, such as UCB cell type, timing of administration and dosage, have on the efficacy of UCB-derived cell therapy in animal models of perinatal brain injury. We identified UCBCs to show greater efficacy in the brain injury model of IVH compared to HI, the use of UCB-derived MSCs compared to MNCs and the use of local administrative routes compared to systemic routes. In addition to this, we identified knowledge gaps such as the limited preclinical literature surrounding the effect of dose number and sex.

show abstract

“…Human umbilical cord blood mononuclear cells, which are isolated from the umbilical cord blood of pregnant women after delivery, are mononuclear cells and the largest cells in the human body; these cells include a variety of stem cells, lymphocytes and monocytes 14 . HUCB-MNCs have a variety of biological functions, such as tissue and cell regeneration, anti-inflammatory effects, and immune regulation 14 . Umbilical cord blood mononuclear cells can differentiate into a variety of immune cells as needed and can expand into a large number of highly active immune cells in vitro.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel disease

Cai,

Li,

Gao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Ischaemic bowel disease (ICBD) is a group of intestinal ischaemia syndromes caused by various aetiologies of reduced intestinal blood flow or vascular occlusion. ICBD can present as abdominal pain, bloody stool, and diarrhoea. This disease often occurs in middle-aged and elderly individuals with cardiovascular and cerebrovascular diseases. The incidence of ischaemic bowel disease has been increasing for decades, and it is difficult to diagnose, resulting in rapid disease progression and a high mortality rate. Therefore, fully understanding this disease, improving the diagnosis rate of this disease, and finding appropriate treatment methods are urgently needed to improve the condition and prognosis of patients. Umbilical cord blood stem cells are accessible, have weak immunogenicity, and have various biological functions, such as angiogenesis, inflammation and immune regulation. Many studies have confirmed that cord blood stem cells can relieve ischaemia, and these cells have attracted tremendous amounts of attention in regenerative medicine in recent years. In this paper, we discuss the clinical characteristics of ICBD, analyse the characteristics of human umbilical cord blood mononuclear cells (HUCB-MNCs), and use its to treat ischaemic bowel disease. Additionally, we compare the clinical manifestations and related indicators before and after treatment to evaluate the efficacy and safety of these methods.

show abstract

Human umbilical cord blood mononuclear cells transplantation for perinatal brain injury

Cited by 21 publications

References 67 publications

Umbilical cord mesenchymal stem cell; a potential therapy on reducing intimal hyperplasia in rabbit arteriovenous fistula (AVF) model, analysis the expression of HIF-1a, eNOS, and MMP-2

Umbilical cord mesenchymal stem cell; a potential therapy on reducing intimal hyperplasia in rabbit arteriovenous fistula (AVF) model, analysis the expression of HIF-1a, eNOS, and MMP-2

Umbilical cord blood-derived cell therapy for perinatal brain injury: A systematic review & meta-analysis of preclinical studies - Part B

Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel disease

Contact Info

Product

Resources

About